Clinical outcomes are complex and often involve multiple systemic burdens. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological biopsies.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of ALL requires individualized development, usually including multidimensional management, such as drug therapy, rehabilitation, and regular follow-up visits. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of multiple myeloma. The platform serves the China International Medical Service System, a national and international team of authoritative experts in the field of autoimmune and rheumatic immunity, to provide the following services to patients: 1.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.